Inclusion Criteria:  Male or female aged 18 years or older at screening Has provided written informed consent for participation in the study Must have risk factors for HCC e.g. cirrhosis, chronic hepatitis B infection with or without cirrhosis Patients with liver lesions ≥1 cm suspicious for HCC but with indeterminate features on CT and MRI meeting LI-RADS 3 or 4 criteria planned for biopsy, OR patients with liver lesions diagnostic of HCC based on CT or MRI meeting LI-RADS 5 criteria planned for surgical resection Patients must be willing and able to comply with the protocol and procedures for the duration of the study Patients must be available for follow-up  Exclusion Criteria:  Abdominal surgery or radiotherapy to the abdomen within <4 weeks of registration. Patients must have recovered from any effects of any major surgery Uncontrolled intercurrent illness that is likely to impede participation and or compliance Any history of prostate cancer or elevated PSA level for male patients Other malignancies unless curatively treated with no evidence of disease within previous 3-years other than adequately treated non-melanoma skin cancer or melanoma in situ Participation in another clinical study with an investigational product or another systemic cancer therapy administered in the last 4 weeks Has known psychiatric or substance abuse disorders that would interfere with cooperation with requirements of the study Women who are pregnant or lactating Cirrhosis due to congenital hepatic fibrosis, vascular disorders (e.g. Budd-Chiari syndrome) or cardiac cirrhosis